March Altus Capital Management Lp buys $2 Million stake in Eli Lilly and Co (LLY)

Eli Lilly and Co (LLY) : March Altus Capital Management Lp scooped up 17,912 additional shares in Eli Lilly and Co during the most recent quarter end , the firm said in a disclosure report filed with the SEC on May 12, 2016. The investment management firm now holds a total of 26,810 shares of Eli Lilly and Co which is valued at $2 Million.Eli Lilly and Co makes up approximately 20.61% of March Altus Capital Management Lp’s portfolio.

Other Hedge Funds, Including , Pegasus Partners Ltd. reduced its stake in LLY by selling 6,380 shares or 28.41% in the most recent quarter. The Hedge Fund company now holds 16,075 shares of LLY which is valued at $1.2 Million. Eli Lilly and Co makes up approx 0.68% of Pegasus Partners Ltd.’s portfolio.Blackrock Institutional Trust Company N.a. reduced its stake in LLY by selling 64,592 shares or 0.24% in the most recent quarter. The Hedge Fund company now holds 26,384,365 shares of LLY which is valued at $2,013.9 Million. Eli Lilly and Co makes up approx 0.34% of Blackrock Institutional Trust Company N.a.’s portfolio.Finemark National Bank Trust boosted its stake in LLY in the latest quarter, The investment management firm added 1,257 additional shares and now holds a total of 27,649 shares of Eli Lilly and Co which is valued at $2.1 Million. Eli Lilly and Co makes up approx 0.25% of Finemark National Bank Trust’s portfolio.Winslow Asset Management Inc reduced its stake in LLY by selling 9,455 shares or 12.07% in the most recent quarter. The Hedge Fund company now holds 68,876 shares of LLY which is valued at $5.3 Million. Eli Lilly and Co makes up approx 1.21% of Winslow Asset Management Inc’s portfolio.

Eli Lilly and Co opened for trading at $74.79 and hit $75.54 on the upside on Friday, eventually ending the session at $74.81, with a gain of 0.67% or 0.5 points. The heightened volatility saw the trading volume jump to 46,89,174 shares. Company has a market cap of $82,578 M.

On the company’s financial health, Eli Lilly and Co reported $0.83 EPS for the quarter, missing the analyst consensus estimate by $ -0.02 based on the information available during the earnings call on Apr 26, 2016. Analyst had a consensus of $0.85. The company had revenue of $4865.10 million for the quarter, compared to analysts expectations of $4829.37 million. The company’s revenue was up 4.7% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.87 EPS.

Many Wall Street Analysts have commented on Eli Lilly and Co. Company shares were Reiterated by Leerink Partners on May 2, 2016 to “Outperform”, Firm has raised the Price Target to $ 101 from a previous price target of $96 .Societe Generale Initiated Eli Lilly and Co on Apr 6, 2016 to “Hold”, Price Target of the shares are set at $78.

Eli Lilly and Company (Lilly) is engaged in drug manufacturing business. The Company discovers develops manufactures and market products in two segments: human pharmaceutical products and animal health products. The Company’s products are sold in approximately 120 countries. The Company’s human pharmaceutical business segment sells medicines which are discovered or developed by its scientists. Its animal health business segment operates through the Company’s Elanco division which develops manufactures and markets products for both food animals and companion animals. The Company manufactures and distributes its products through facilities in the United States Puerto Rico and 11 other countries. Its products include endocrinology products neuroscience products oncology products cardiovascular products products for food animals products for companion animals and Novartis AH products.

Leave a Reply

Eli Lilly and Co - Is it time to Sell?

Top Brokerage Firms are advising their investors on Eli Lilly and Co. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.